Abstract

Purpose: To evaluate the association of prior to intensive care unit (ICU) statin use with the clinical outcomes in critically ill patients with acute kidney injury (AKI).Materials and Methods: Patients with AKI were selected from the Medical Information Mart for Intensive Care IV (version 1.0) database for this retrospective observational study. The primary outcome was 30-day intensive care unit (ICU) mortality. A 30-day in-hospital mortality and ICU length of stay (LOS) were considered as secondary outcomes. Comparison of mortality between pre-ICU statin users with non-users was conducted by the multivariate Cox proportional hazards model. Comparison of ICU LOS between two groups was implemented by multivariate linear model. Three propensity score methods were used to verify the results as sensitivity analyses. Stratification analyses were conducted to explore whether the association between pre-ICU statin use and mortality differed across various subgroups classified by sex and different AKI stages.Results: We identified 3,821 pre-ICU statin users and 9,690 non-users. In multivariate model, pre-ICU statin use was associated with reduced 30-day ICU mortality rate [hazard ratio (HR) 0.68 (0.59, 0.79); p < 0.001], 30-day in-hospital mortality rate [HR 0.64 (0.57, 0.72); p < 0.001] and ICU LOS [mean difference −0.51(−0.79, −0.24); p < 0.001]. The results were consistent in three propensity score methods. In subgroup analyses, pre-ICU statin use was associated with decreased 30-day ICU mortality and 30-day in-hospital mortality in both sexes and AKI stages, except for 30-day ICU mortality in AKI stage 1.Conclusion: Patients with AKI who were administered statins prior to ICU admission might have lower mortality during ICU and hospital stay and shorter ICU LOS.

Highlights

  • Due to the abrupt decline in kidney function, including reversible or irreversible, acute kidney injury (AKI) can lead to retention of metabolic waste products within a short time [1]

  • Pre-intensive care unit (ICU) statin use was associated with reduced 30-day ICU mortality rate [hazard ratio (HR) 0.68 (0.59, 0.79); p < 0.001], 30-day in-hospital mortality rate [Hazard ratios (HRs) 0.64 (0.57, 0.72); p < 0.001] and ICU length of stay (LOS) [mean difference −0.51(−0.79, −0.24); p < 0.001]

  • Pre-ICU statin use was associated with decreased 30-day ICU mortality and 30-day in-hospital mortality in both sexes and AKI stages, except for 30-day ICU mortality in AKI stage 1

Read more

Summary

Introduction

Due to the abrupt decline in kidney function, including reversible or irreversible, acute kidney injury (AKI) can lead to retention of metabolic waste products within a short time [1]. Patients with AKI experience water and sodium retention, oliguria or even anuria, hyperkalemia, metabolic acidosis, acute pulmonary edema, cerebral edema, and other complications. AKI is common in hospitalized patients and intensive care unit (ICU) patients. Patients with multiple risk factors such as sepsis, surgery, shock, diabetes, hypertension, heart failure, advanced age, use of contrast agents and nephrotoxic drugs, and those critically ill in the ICU often have a higher prevalence of AKI and increased mortality rates [2]. 20% of critically ill patients develop AKI in hospital and approximately 10% of them eventually require renal replacement therapy (RRT). AKI progresses rapidly and given the current lack of specific pharmacological treatments, current treatment guidelines focus on supportive care and dialysis [1]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call